COMMUNIQUÉS West-GlobeNewswire

Mesoblast’s Phase 3 Trial in Children With Acute Graft Versus Host Disease Completes Enrollment

20/12/2017 - 12:00

NEW YORK and MELBOURNE, Australia, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that the Phase 3 trial of its proprietary allogeneic mesenchymal stem cell (MSC) product [...]

Changes to the Executive Leadership Team

20/12/2017 - 11:59

Novozymes announces the appointment of Ms. Prisca Havranek-Kosicek as new Chief Financial Officer effective February 1, 2018. Ms. Havranek-Kosicek has up until November 2017 served as CFO and member of the Executive [...]

Adventist Health Promotes Joe Reppert as Chief Financial Officer

20/12/2017 - 11:30

ROSEVILLE, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Adventist Health —a non-profit integrated health system serving more than 75 communities on the West Coast and in Hawaii—is proud to announce the recent promotion of [...]

ALK – Financial calendar for the 2018 financial year

20/12/2017 - 11:06

Copenhagen, 2017-12-20 11:06 CET (GLOBE NEWSWIRE) -- 2018 financial calendar for ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ): Silent period 9 January 2018 Annual report 2017 6 February 2018 Annual General Meeting to be [...]

NeuroSearch – financial calendar for 2018

20/12/2017 - 08:00

Announcement no. 9-17 Page 1 of 1 Announcement 20 December 2017 NeuroSearch A/S (NEUR) hereby announces the company’s financial calendar for 2018. 9 February 2018 Annual Report 2017 25 April 2018 Annual General Meeting [...]

TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform

20/12/2017 - 07:01

PRESS RELEASE TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform Leuven (BELGIUM) - December 20, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix" or " [...]

TiGenix confirme l'orientation stratégique du Cx601 et de la plateforme de cellules souches dérivées de tissus adipeux (eASC)

20/12/2017 - 07:01

COMMUNIQUÉ DE PRESSE TiGenix confirme l'orientation stratégique du Cx601 et de la plateforme de cellules souches dérivées de tissus adipeux (eASC) Louvain (BELGIQUE) - 20 décembre 2017, 07h. CET - TiGenix NV (Euronext [...]

MPX Bioceutical Corporation Provides Update on Private Placement

20/12/2017 - 01:59

TORONTO, Dec. 19, 2017 (GLOBE NEWSWIRE) -- MPX Bioceutical Corp. (the “ Company ” or “ MPX ”) (CSE:MPX) (OTC:MPXEF) is pleased to provide this corporate update concerning its previously announced brokered private [...]

Skyline Medical Acquiring up to 25% Equity Stake in Helomics Corporation, a Precision Diagnostics Company

19/12/2017 - 23:30

MINNEAPOLIS, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ: SKLN ) (“Skyline” or the “Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, [...]

Catalyst Biosciences Announces Proposed Public Offering of Common Stock

19/12/2017 - 22:51

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology [...]

ProPhase Labs, Inc. Announces Preliminary Results of Its Tender Offer

19/12/2017 - 22:30

DOYLESTOWN, Pa., Dec. 19, 2017 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH ) ( www.ProPhaseLabs.com ), a diversified natural health medical science company (“ProPhase”), announced today the preliminary results [...]

Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Into 2019

19/12/2017 - 22:10

NORCROSS, Ga., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured [...]

Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreement for FPA144 Anti-FGFR2b Antibody in Greater China and Global Strategic Development Collaboration

19/12/2017 - 22:05

SOUTH SAN FRANCISCO, Calif. and SHANGHAI, China, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc . (NASDAQ: FPRX ), a biotechnology company discovering and developing innovative immuno-oncology protein [...]

SDi Announces Planned Release of 2018 Global Assessment Report

19/12/2017 - 21:44

LOS ANGELES, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Strategic Directions International (SDi), a division of BioInformatics LLC, announced today the 2018 Global Assessment Report: The Laboratory Analytical & Life [...]

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl), a One-time Gene Therapy for Patients with Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy

19/12/2017 - 21:05

LUXTURNA is first gene therapy for a genetic disease, first and only pharmacologic treatment for an inherited retinal disease (IRD) and first adeno-associated virus (AAV) vector gene therapy approved in U.S. Children [...]

Qu Biologics invited to present research data at inaugural Crohn’s and Colitis Congress

19/12/2017 - 18:45

VANCOUVER, British Columbia, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore [...]

APHL Announces Newborn Screening Funding Recipients

19/12/2017 - 16:41

Silver Spring, MD, Dec. 19, 2017 (GLOBE NEWSWIRE) -- For Immediate Release The Association of Public Health Laboratories (APHL) is pleased to announce the recipients of the second round of New Disorders Implementation [...]

U.S. Food and Drug Administration Approves Prior Approval Supplement for Commercial Launch of Portola Pharmaceuticals’ Novel Oral Anticoagulant Bevyxxa® (betrixaban)

19/12/2017 - 16:35

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA ) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Prior Approval [...]

Apellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial Officer

19/12/2017 - 16:16

CRESTWOOD, Ky. and CAMBRIDGE, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc., (Nasdaq: APLS ) a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for [...]